Fig. 8

Therapeutic efficacy of FZ/MER-AgMOF@Bm against CLP-induced sepsis in mice. (A) Schematic diagram of experimental design for sepsis therapy. (B) Plasma IL-1β, IL-6 and IL-10 levels from mice injected with normal saline, AgMOF (7.5 mg/kg), FPS-ZM1 (1.5 mg/kg), meropenem (1.5 mg/kg), FZ/MER-AgMOF (FPS-ZM1 dose of 1.5 mg/kg) or FZ/MER-AgMOF@Bm (FPS-ZM1 dose of 1.5 mg/kg) 2 h after CLP challenge (n = 5). (C) Body temperature change curves of mice receiving different treatments (n = 5). (D) Kaplan-Meier survival plots for each treatment group (n = 4 of control group, n = 8 of other treatment groups). (E) Representative images of H&E staining and IHC staining of LY6G, TNF-α and IL-6 in lungs (n = 5). (F) Representative images of H&E staining for livers (n = 5). con: Sham mice treating with saline; CLP: cecal ligation and puncture; Scale bar: 100 μm. Data are derived from three independent experiments and presented as mean ± SEM in the bar graphs. *P < 0.05, ***P < 0.001, ns: not significant